Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Clovis Oncology Inc's Business Segments
Clovis Oncology Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q3 FY2022
Reportable Segments
2
Largest Segment
US Segment
Total Revenue
$ 31
Regions Reported
-
Revenue Share by Reportable Segment - Q3 FY2022
- US Segment75.1%
- Outside U.s.Segment24.9%
Revenue by Reportable Segment - Q3 FY2022
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| US Segment | $ 23 | 75.1% |
| Outside U.s.Segment | $ 8 | 24.9% |
Description of Clovis Oncology Inc
Clovis Oncology Inc. is a biopharmaceutical company that is focused on developing innovative anti-cancer treatments. The company was founded in 2009 and is headquartered in Boulder, Colorado. Its stock is traded on the NASDAQ global market under the ticker symbol CLVS.
Clovis Oncology is engaged in the research, development, and commercialization of anti-cancer treatments that target specific genetic mutations that are found in certain forms of cancer. The company's flagship product is Rubraca (rucaparib), an oral, small-molecule inhibitor of poly (ADP-ribose) polymerase (PARP) that is approved in the United States and other countries for the treatment of recurrent ovarian cancer.
Clovis Oncology's pipeline includes several other promising products, including LUCA-19, a monoclonal antibody that targets the protein CD19, which is expressed on the surface of certain blood cancers. Another promising product is FAP-2286, a small molecule drug that targets fibroblast activation protein (FAP), a protein that is found in the stroma of many solid tumors.
The company is led by a management team with deep experience in the biopharmaceutical industry. It has partnerships and collaboration agreements with several other biotechnology and pharmaceutical companies, including Pfizer and Bristol-Myers Squibb.
Clovis Oncology is committed to creating innovative treatments for cancer patients, and its cutting-edge research and development programs have the potential to change the way cancer is treated in the future. Despite setbacks in clinical trials, the company continues to push forward and explore new avenues for cancer treatment.
Clovis Oncology is engaged in the research, development, and commercialization of anti-cancer treatments that target specific genetic mutations that are found in certain forms of cancer. The company's flagship product is Rubraca (rucaparib), an oral, small-molecule inhibitor of poly (ADP-ribose) polymerase (PARP) that is approved in the United States and other countries for the treatment of recurrent ovarian cancer.
Clovis Oncology's pipeline includes several other promising products, including LUCA-19, a monoclonal antibody that targets the protein CD19, which is expressed on the surface of certain blood cancers. Another promising product is FAP-2286, a small molecule drug that targets fibroblast activation protein (FAP), a protein that is found in the stroma of many solid tumors.
The company is led by a management team with deep experience in the biopharmaceutical industry. It has partnerships and collaboration agreements with several other biotechnology and pharmaceutical companies, including Pfizer and Bristol-Myers Squibb.
Clovis Oncology is committed to creating innovative treatments for cancer patients, and its cutting-edge research and development programs have the potential to change the way cancer is treated in the future. Despite setbacks in clinical trials, the company continues to push forward and explore new avenues for cancer treatment.
Clovis Oncology Inc. is a biopharmaceutical company deeply entrenched in the oncology sector, focusing on the development and commercialization of innovative treatments tailored for patients battling cancer. The organization prioritizes precision medicine, which entails creating targeted therapies that address specific genetic mutations or biomarkers present within tumors.
Segments
Clovis Oncology’s operations are primarily stratified into two distinct segments:
1. Product Sales: This segment generates revenue through the sales of the company’s approved therapies. Key products include:
- Rubraca (rucaparib): A small molecule inhibitor classified as a PARP (poly-ADP ribose polymerase) inhibitor. Rubraca is primarily indicated for the treatment of patients with advanced ovarian cancer who have undergone two or more prior lines of chemotherapy. The product has been recognized for its ability to leverage the unique genetic profile of patients’ tumors, specifically those with homologous recombination deficiency (HRD) or BRCA mutations, enabling a more precise therapeutic approach.
- Lucitanib: An oral tyrosine kinase inhibitor currently under investigation in clinical trials. Lucitanib targets multiple pathways, including VEGFR, FGFR, and PDGFR, and is being explored as a possible treatment for various advanced solid tumors. This product reflects Clovis Oncology’s commitment to addressing the unmet medical needs in oncology by providing comprehensive treatment regimens.
2. Clinical Development: This segment focuses on the research and development of innovative cancer therapies that are still in varying phases of clinical trials. Clovis is dedicated to expanding its pipeline, which includes several potential drug candidates being evaluated for their efficacy and safety across different types of cancer. This commitment to clinical development underscores the company’s focus on transforming cancer treatment landscapes and improving therapeutic outcomes for patients.
Products
Clovis Oncology boasts a targeted portfolio of products, showcasing its innovative approach to cancer treatment:
1. Rubraca (rucaparib):
- Indications: Approved for patients with advanced ovarian cancer, particularly those with HRD-positive tumors or BRCA mutations after receiving two previous chemotherapy regimens.
- Mechanism of Action: Rubraca exploits the concept of synthetic lethality, where the inhibition of PARP leads to the accumulation of DNA damage in cancer cells already deficient in homologous recombination repair, promoting tumor cell death.
2. Lucitanib:
- Indications: Currently in clinical trials for treatment of advanced solid tumors.
- Mechanism of Action: As a multi-targeted tyrosine kinase inhibitor, Lucitanib disrupts several pathways crucial for tumor growth and survival. This broad approach allows for a potentially effective treatment regimen against various malignancies.
Services
In addition to developing and selling its innovative therapies, Clovis Oncology extends its services to ensure comprehensive support for patients, their families, and healthcare providers:
- Patient Support Programs: These programs are instrumental in aiding patients in navigating the complexities of cancer treatment. They provide educational resources and assist with managing the side effects related to cancer therapies. Through coordinated efforts with healthcare professionals, Clovis ensures that patients receive holistic care that addresses both clinical needs and personal well-being.
- Healthcare Provider Education: Clovis also engages in educational initiatives aimed at healthcare professionals to facilitate the optimal use of its therapies. By offering training sessions, informational resources, and support materials, the company fosters a better understanding of its products and their applications in clinical settings.
Summary
Clovis Oncology Inc. stands as a beacon of innovation in the biopharmaceutical arena, specifically tailored to the unique challenges presented by cancer. With a concentrated focus on precision medicine, the company operates through product sales and clinical development segments. Its flagship products, Rubraca and Lucitanib, exemplify its commitment to tackling cancer at its genetic roots. Furthermore, Clovis’s dedication to supporting patients and healthcare providers through comprehensive services underlines its mission to enhance cancer care and improve patient outcomes.
Segments
Clovis Oncology’s operations are primarily stratified into two distinct segments:
1. Product Sales: This segment generates revenue through the sales of the company’s approved therapies. Key products include:
- Rubraca (rucaparib): A small molecule inhibitor classified as a PARP (poly-ADP ribose polymerase) inhibitor. Rubraca is primarily indicated for the treatment of patients with advanced ovarian cancer who have undergone two or more prior lines of chemotherapy. The product has been recognized for its ability to leverage the unique genetic profile of patients’ tumors, specifically those with homologous recombination deficiency (HRD) or BRCA mutations, enabling a more precise therapeutic approach.
- Lucitanib: An oral tyrosine kinase inhibitor currently under investigation in clinical trials. Lucitanib targets multiple pathways, including VEGFR, FGFR, and PDGFR, and is being explored as a possible treatment for various advanced solid tumors. This product reflects Clovis Oncology’s commitment to addressing the unmet medical needs in oncology by providing comprehensive treatment regimens.
2. Clinical Development: This segment focuses on the research and development of innovative cancer therapies that are still in varying phases of clinical trials. Clovis is dedicated to expanding its pipeline, which includes several potential drug candidates being evaluated for their efficacy and safety across different types of cancer. This commitment to clinical development underscores the company’s focus on transforming cancer treatment landscapes and improving therapeutic outcomes for patients.
Products
Clovis Oncology boasts a targeted portfolio of products, showcasing its innovative approach to cancer treatment:
1. Rubraca (rucaparib):
- Indications: Approved for patients with advanced ovarian cancer, particularly those with HRD-positive tumors or BRCA mutations after receiving two previous chemotherapy regimens.
- Mechanism of Action: Rubraca exploits the concept of synthetic lethality, where the inhibition of PARP leads to the accumulation of DNA damage in cancer cells already deficient in homologous recombination repair, promoting tumor cell death.
2. Lucitanib:
- Indications: Currently in clinical trials for treatment of advanced solid tumors.
- Mechanism of Action: As a multi-targeted tyrosine kinase inhibitor, Lucitanib disrupts several pathways crucial for tumor growth and survival. This broad approach allows for a potentially effective treatment regimen against various malignancies.
Services
In addition to developing and selling its innovative therapies, Clovis Oncology extends its services to ensure comprehensive support for patients, their families, and healthcare providers:
- Patient Support Programs: These programs are instrumental in aiding patients in navigating the complexities of cancer treatment. They provide educational resources and assist with managing the side effects related to cancer therapies. Through coordinated efforts with healthcare professionals, Clovis ensures that patients receive holistic care that addresses both clinical needs and personal well-being.
- Healthcare Provider Education: Clovis also engages in educational initiatives aimed at healthcare professionals to facilitate the optimal use of its therapies. By offering training sessions, informational resources, and support materials, the company fosters a better understanding of its products and their applications in clinical settings.
Summary
Clovis Oncology Inc. stands as a beacon of innovation in the biopharmaceutical arena, specifically tailored to the unique challenges presented by cancer. With a concentrated focus on precision medicine, the company operates through product sales and clinical development segments. Its flagship products, Rubraca and Lucitanib, exemplify its commitment to tackling cancer at its genetic roots. Furthermore, Clovis’s dedication to supporting patients and healthcare providers through comprehensive services underlines its mission to enhance cancer care and improve patient outcomes.